Last reviewed · How we verify
Clopidogrel and Dexlansoprazole
At a glance
| Generic name | Clopidogrel and Dexlansoprazole |
|---|---|
| Also known as | Plavix, Kapidex, TAK-390MR |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program (NA)
- Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. (NA)
- A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants. (PHASE1)
- Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel (PHASE1)
- Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel and Dexlansoprazole CI brief — competitive landscape report
- Clopidogrel and Dexlansoprazole updates RSS · CI watch RSS
- Takeda portfolio CI